Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glutamine for VOC Prevention in Pediatric SCD
NCT05371184Phase 4Completed
- Sponsor
- Ain Shams University
- Start
- Jan 2022
- Primary completion
- Jan 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of glutamine in sickle cell disease (SCD) (2 arms), sponsored by Ain Shams University. Primary endpoint: Number of pain crises at 24 weeks. Started Jan 2022; status: completed.
02
Drugs
glutamine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05371184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05371184.